# C_2016378EN.01002201.xml

| 14.10.2016 | EN | Official Journal of the European Union | C 378/22 |
| --- | --- | --- | --- |

14.10.2016

EN

Official Journal of the European Union

C 378/22

---

Prior notification of a concentration

(Case M.8219 — Clayton, Dubilier & Rice, Inc./Medical Depot Holdings, Inc.)

Candidate case for simplified procedure

(Text with EEA relevance)

(2016/C 378/11)

| 1. | On 5 October 2016, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which CD&R Reign Topco, Inc. ultimately controlled by Clayton, Dubilier & Rice, Inc. (‘CD&R’, United States) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Medical Depot Holdings, Inc., doing business as Drive DeVilbiss Healthcare (‘Drive’, United States), by way of purchase of shares. |
| --- | --- |

1.

On 5 October 2016, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which CD&R Reign Topco, Inc. ultimately controlled by Clayton, Dubilier & Rice, Inc. (‘CD&R’, United States) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Medical Depot Holdings, Inc., doing business as Drive DeVilbiss Healthcare (‘Drive’, United States), by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   for CD&R: an equity investor in management buyouts, strategic minority equity investments and other strategic investments through funds controlling a number of portfolio companies which are active in a variety of economic sectors, globally,
  —   for Drive: manufacturing and distribution of medical equipment, including mobility products, sleep and respiratory products, beds, bariatric products, wheelchairs, sleep surfaces and pressure prevention products, self-assist products, power operated wheelchairs, rehabilitation products, patient room equipment, personal care products and electrotherapy devices, predominantly for patients’ home care needs, globally. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for CD&R: an equity investor in management buyouts, strategic minority equity investments and other strategic investments through funds controlling a number of portfolio companies which are active in a variety of economic sectors, globally,

for CD&R

—   for Drive: manufacturing and distribution of medical equipment, including mobility products, sleep and respiratory products, beds, bariatric products, wheelchairs, sleep surfaces and pressure prevention products, self-assist products, power operated wheelchairs, rehabilitation products, patient room equipment, personal care products and electrotherapy devices, predominantly for patients’ home care needs, globally.

for Drive

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8219 — Clayton, Dubilier & Rice, Inc./Medical Depot Holdings, Inc., to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8219 — Clayton, Dubilier & Rice, Inc./Medical Depot Holdings, Inc., to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---